The Pfizer New Haven Clinical Research Unit is conducting a clinical trial of an oral study drug for certain types of breast cancer. This study will look at the effects of the study drug when combined with an additional medication after an overnight fast.
Worldwide, breast cancer is the most common invasive cancer, with more than 2.2 million people impacted annually. Metastatic breast cancer, the most advanced stage of breast cancer in which the cancer has spread to other parts of the body (i.e., organs, bones), remains an incurable disease.
We are committed to supporting patients by developing innovative medicines that have the potential to help people with various types of breast cancer. Learn how you can help as a healthy volunteer below.
Who may participate
Clinical trial participants are an essential part of discovering new or better ways to treat disease.
This study is seeking healthy adult volunteers, meaning that the participants will not have the condition being studied and are in overall good health. In addition to the criteria listed, participants must meet the following requirements:
- Willing to take a study drug
- Willing and able to come to our facility in New Haven, CT*
- Willing and able to comply with all study procedures
*participants may be eligible to receive a bonus for travel, ask our staff for details
**females must be unable to bear children
There are other requirements for participation in this study. The study staff will explain these to you during the screening process.
Do you know someone who may meet these requirements? Refer a friend and you may be eligible to receive a bonus.
Condition
Healthy
Age
18-99 years
Sex
All sexes**
Referral bonus
Up to $150
Each clinical study has its own guidelines for who can participate, called eligibility criteria. However, only the research study staff can determine if you qualify to enroll in the study.
What to expect
If this study may be a fit for you, you’ll be invited to a screening visit at our facility in New Haven, CT. If you qualify for the study, there may be a period of up to 28 days before dosing.
If you choose to participate, you will stay at our facility for 27 consecutive overnights. The morning after your admission, you will receive a single dose of the study drug as a tablet to swallow. This will be given after fasting overnight. About 2 weeks later, you will begin receiving doses of another medication as a liquid to swallow, once a day for 12 days. On the 4th day of receiving this medication, you will also receive another single dose of the study drug.
Throughout the study, staff will closely monitor your health status and collect data, such as the levels of the study drug in your blood.
This study requires you to stay at the PCRU for the entire duration listed unless you choose to withdraw. You can learn more about what to expect during your participation by browsing our FAQ section.
Required overnight stays
27 consecutive overnights
Long-term follow up
1 phone call
How long is this study?
About 55 days
Compensation
Up to $12,250 upon completion of the study
All of the study procedures will be clearly explained to you during screening and can be viewed in the informed consent form.